Cancer Immunotherapy News and Research

RSS

Synthetic IL-9 receptor allows T cells to fight cancer without the need for chemo or radiation

Before a patient can undergo T cell therapy designed to target cancerous tumors, the patient's entire immune system must be destroyed with chemotherapy or radiation. The toxic side effects are well known, including nausea, extreme fatigue and hair loss.

8 Jun 2022

New microbubble-assisted ultrasound-guided immunotherapy helps improve anti-tumor immunity

Researchers at UT Southwestern have developed a first-of-its-kind ultrasound-guided cancer immunotherapy platform that delivers immune-stimulating agents to cells for the development of systemic anti-tumor immunity.

7 Jun 2022

Chemo-immunotherapy combination shows promise against pancreatic cancer

A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, and sponsored by the Parker Institute for Cancer Immunotherapy.

6 Jun 2022

Liquid biopsy could better predict immunotherapy response in lung cancer patients than tumor biopsy

Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.

3 Jun 2022

New discovery could pave the way for more effective cancer immunotherapy

A type of white blood cell previously known only as a helper in the immune system appears also to be the instigator of the body's defenses against cancerous tumors.

31 May 2022

New compounds for cancer immunotherapy via STING-mediated immune activation

Innovations in cancer immunotherapy have achieved clinical success by considerably increasing the survival rate of patients undergoing cancer treatment.

31 May 2022

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade.

30 May 2022

Immunogenicity predictions reveal SARS-CoV-2 CD8+ T-cell epitopes

In a recent study posted to the bioRxiv* pre-print server, researchers identified several new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epitopes displayed on human leukocyte antigens class I (HLA-I) molecules.

26 May 2022

New initiative aims to increase collaboration and accelerate high-impact cancer immunotherapy

The accelerated advancement of cancer immunology and immunotherapy, a type of biological therapy that boosts the immune system's ability to recognize and kill cancer cells, has significantly improved the effectiveness of cancer treatment and patient outcomes.

25 May 2022

Penn Medicine and CHOP announce plans with Costa Rica's CCSS for CAR T research

Penn Medicine and Children's Hospital of Philadelphia, who together pioneered the research and development of the world's first personalized cellular therapy for cancer - also known as CAR T cell therapy - have announced plans with Costa Rica's CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica.

23 May 2022

Exosomes derived from γδ-T cells synergized with radiotherapy can control nasopharyngeal carcinoma

A research team at LKS Faculty of Medicine, The University of Hong Kong discovered that exosomes derived from γδ-T cells (γδ-T-Exos) synergised with radiotherapy can control nasopharyngeal carcinoma (NPC) by overcoming the radioresistance of NPC cancer stem cells (CSCs) and preserve their tumor-killing and T cell-promoting activities in the immunosuppressive NPC microenvironment.

18 May 2022

World's first Focused Ultrasound Cancer Immunotherapy Center could revolutionize cancer care

UVA Health and the Charlottesville-based Focused Ultrasound Foundation today announced the launch of the Focused Ultrasound Cancer Immunotherapy Center, the world's first center dedicated specifically to advancing a focused ultrasound and cancer immunotherapy treatment approach that could revolutionize 21st-century cancer care.

11 May 2022

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Immune checkpoint inhibitors are widely used to treat a variety of cancers; however, one serious side effect is the onset of type 1 diabetes.

6 May 2022

Discovery provides critical clues to why many immunotherapies trigger dangerous side effects

It's not often that a failed clinical trial leads to a scientific breakthrough. When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.

5 May 2022

Exploring oncolytic viral therapeutics and immunotherapies derived from DNA and RNA

A new review initially described the developments in cancer-based medicines that included vaccinations, vector-based techniques, and genome injection using DNA and RNA-based nucleic acid therapeutics.

28 Apr 2022

Study illuminates why cowpea mosaic virus is exceptionally effective against cancer

A plant virus that infects legumes, called cowpea mosaic virus, has a special power that you may not have known about: when injected into a tumor, it triggers the immune system to treat the cancer - even metastatic cancer - and prevents it from recurring.

27 Apr 2022

A potential way for overcoming immunotherapy resistance in patients with mucosal melanomas

The development of the anti-cancer immunotherapy drugs called immune checkpoint inhibitors has improved treatment for many cancer patients, but patients with mucosal melanomas - melanomas that occur not on the skin but in the mucous membranes in the head, neck, eyes, respiratory tract, and genitourinary region - are particularly resistant to immune checkpoint inhibitors for reasons researchers don't fully understand.

25 Apr 2022

Cancer Immunotherapy News and Research

Synthetic IL-9 receptor allows T cells to fight cancer without the need for chemo or radiation

New microbubble-assisted ultrasound-guided immunotherapy helps improve anti-tumor immunity

Chemo-immunotherapy combination shows promise against pancreatic cancer

Liquid biopsy could better predict immunotherapy response in lung cancer patients than tumor biopsy

New discovery could pave the way for more effective cancer immunotherapy

New compounds for cancer immunotherapy via STING-mediated immune activation

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Immunogenicity predictions reveal SARS-CoV-2 CD8+ T-cell epitopes

New initiative aims to increase collaboration and accelerate high-impact cancer immunotherapy

Penn Medicine and CHOP announce plans with Costa Rica's CCSS for CAR T research

Exosomes derived from γδ-T cells synergized with radiotherapy can control nasopharyngeal carcinoma

World's first Focused Ultrasound Cancer Immunotherapy Center could revolutionize cancer care

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Discovery provides critical clues to why many immunotherapies trigger dangerous side effects

Exploring oncolytic viral therapeutics and immunotherapies derived from DNA and RNA

Study illuminates why cowpea mosaic virus is exceptionally effective against cancer

A potential way for overcoming immunotherapy resistance in patients with mucosal melanomas

Newly discovered immune cell "soldier" could be a good target for immunotherapy

CAR T-Cell Therapy: The Future of Cancer and HIV Treatment?

A comprehensive rule book for the design of safe and efficient therapeutic cells

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News